Minocycline Treatment for Cystoid Macular Edema

• Status: Recruiting
• Trial end date: 2025-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Participant diagnosed with CME.

• Participant aged from 18-60 years old.

• Participant that signed the informed consent document and is able to complete the following visits.

Exclusion Criteria:

• Participant is allergy to minocycline or tetracyclines.

• Participant has no contraindications of minocycline or tetracyclines.

• Participant has an abnormal function of liver, heart, kidney and thyroid.

• Female that is pregnant, breast-feeding or planning to become pregnant.

• Participant that is currently using other medications.